Clinical trial
A Phase Ⅱ Study of Pre-Operative Concurrent Chemoradiotherapy With Capecitabine Plus Irinotecan in Resectable Rectal Cancer.
NCT00506623 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅱ Study of Pre-Operative Concurrent Chemoradiotherapy With Capecitabine Plus Irinotecan in Resectable Rectal Cancer.
- Lead sponsor
- National Cancer Center, Korea
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 31, 2004
- Completion date
- December 31, 2008
- Enrollment
- 48 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
neoadjuvant therapy, rectal neoplasm